Navigation Links
Mach One Corporation Files its Form SB-2 with the SEC
Date:10/16/2007

LAS VEGAS, Oct. 16 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN) is proud to announce that it has filed its SB-2 registration with the Securities and Exchange Commission. The company had announced previously its intention of becoming a fully reporting company under the 1934 Act, and today made it official. The company is next filing to be listed on the OTCBB following the effectiveness of the SB-2. "This is a monumental day for Mach One; we are now poised to move forward as fully reporting company with the next step -- the OTCBB," said Monte Tobin, CEO of Mach One. "Upon the effectiveness of the registration, we will make a public announcement for the benefit of our shareholders and future shareholders.

Mach One Corporation is currently trading on the Pink Sheets, under the symbol MNCN. Upon the effective date of the filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. As a reporting company, Mach One Corporation will be required to file annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, and reports of unusual events on Form 8K. In addition, the Company will be required to solicit proxies for its annual meetings in accordance to Section 14 of the Securities Exchange Act of 1934 and other reporting requirements will apply to management shareholdings.

Investors can view the filing by accessing the SEC's website at http://www.sec.gov.

About Mach One Corporation

The company (http://www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through it's subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution of Immunogam(TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, that can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for the elimination of Mastitis and Johnnes disease.

Cautionary Statement: This news release may include certain "Forward- looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Novartis files application with FDA for Zometa
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
5. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
6. Personality profiles of gamblers and substance abusers are similar
7. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
8. Venus Remedies Files 5th International Patent Application
9. Shoaib Akhtar files appeal against ban
10. AIIMS Official Files Complaint Against Venugopal
11. Glaxo Files Cancer Drug For Approval With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: